Editor's Note: At OBR we have created an editorial board of renown thought leaders in different cancer disease areas. The role of our editorial board is to provide valuable insights through editorial commentary accompanying our daily news. We call it virtual access. By providing our insights into the daily news, you will have access into how these thought leading oncologists interpret the oncology news and events we carry in OBR daily. We hope that our editorial boards's insights will bring great value to the oncology community.
Professor and Chair, Department of Breast Medical Oncology
The University of Texas MD Anderson Cancer Center
This is a long-awaited landmark and registrational trial testing the HER2-specific kinase inhibitor …
Distinguished Professor of Medicine, Rutgers Robert Wood Johnson Medical School
Rutgers-CINJ Associate Director, Clinical Research
Director Clinical Oncology Research, RWJ-B Health System
Kudos to Dr Peter Bach on responding to PhRMA talking points on drug pricing. I am all for R&D …
Executive Director
Community Oncology Alliance
PBMs are getting more brazen in how they delay and deny cancer patients their oral drugs. Anyone in …
National Health Policy Expert
I am somewhat “dazed and confused” by the article entitled “Why the Cancer Moonshot Has Been S…
Professor of Medicine, Division of Hematology/Medical Oncology, School of Medicine
Grover C. Bagby Chair of Prostate Cancer Research
OHSU Knight Cancer Institute Deputy Director, OHSU Knight Cancer Institute, School of Medicine
Chief Medical Officer, CEDAR, OHSU Knight Cancer Institute, School of Medicine
An oral option for primary hormonal therapy will be attractive for some patients, particularly those…
Associate Clinical Professor, Medical Oncology
Executive Director, Employer Services
City of Hope Comprehensive Cancer Center
Duarte, CA
Given the remarkable efficacy of selpercatinib, this is a trial that thoracic oncology experts debat…
President, W-Squared Group
This piece is a great example of a pathway program in process. Clinical pathways are not meant to b…
Professor and Director, Division of Hematology Oncology
Department of Medicine,Cedars-Sinai Medical Center
Associate Director for Academic Program Development
Samuel Oschin Comprehensive Cancer Institute
Professor of Medicine and Urology, Emeritus
David Geffen School of Medicine at UCLA
This long awaited trial performed by the National Cancer Institute demonstrates the benefits of low …
FACP FACPE FASCO
President, Minnesota Oncology
Extremely impressive efficacy in heavily pretreated metastatic HER-2 + breast cancer but the presenc…
CEO
Tennessee Oncology
I found this article both fascinating and enlightening. I had not thought of "burnout" in terms of …
Vice President
Integrated Community Oncology Network
Former Community Representative
ASCO Board of Directors
So a tale of two cities.....it is interesting to compare the oncology alternative payment model to t…
Florida Cancer Specialists
President and Managing Partner
At Florida Cancer Specialists we have been using DigniCap for several months at 3 of our site and it…
Ronald H. Bloom Chair in Cancer Therapeutics
Professor and Chair, Department of Radiation Oncology
Interim Director, Samuel Oschin Comprehensive Cancer Institute
Cedars-Sinai Medical Center
Steve Hahn is very well regarded in the ASTRO community. He's a radiation oncologist who is also boa…
Follow @OBRTweets